Kelly Cappio

Kelly Cappio advises clients on vaccine policy issues and market access strategies.

  With a decade of experience working in the biopharmaceutical sector, Kelly brings deep knowledge of both the vaccine industry and the pre- and post-licensure landscape. 

Prior to joining Avalere, Kelly was the director of government affairs at Novavax, a clinical-stage biotechnology company focused on vaccine development, where she oversaw public policy development and federal legislative strategy and led stakeholder engagement. Before Novavax, she was the director of vaccine and biodefense policy at the Biotechnology Innovation Organization, where her portfolio centered on both domestic and international policies that broadly impact the industry’s development of novel vaccines, antibiotics, and medical countermeasures. Kelly also held a previous role at Sanofi with the federal government affairs team.

Kelly holds an MPH in public health from George Washington University and a BA in international affairs from the University of Colorado at Boulder. She is a member of Phi Beta Kappa and the Delta Omega Honorary Society in Public Health. Kelly was also a 2014 Emerging Leaders in Biosecurity Fellow at the Johns Hopkins Center for Health Security.

Authored Content

A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.

The evolution of the US influenza vaccine market offers insights into the potential barriers and opportunities for successful rollouts of novel COVID-19 vaccines.

On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.

Although influenza disease burden is high, vaccine uptake remains low.

On March 30, Avalere policy experts published a piece in the Health Affairs blog about the existing programs in place to ensure patient access to affordable COVID-19 vaccines.

Opportunities exist to accelerate potential vaccine development.

Tune in to hear the first episode of our podcast series that focuses on COVID-19. In this episode, Avalere experts will discuss COVID-19 vaccinations, focusing on the timeline of development, affordability, and access.

The novel coronavirus (COVID-19) was first reported in Wuhan, China, on December 31, 2019, and within a month was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO).